Neurosense Therapeutics Company Leadership
| NRSN Stock | USD 0.86 0.07 7.53% |
Neurosense Therapeutics employs about 18 people. The company is managed by 12 executives with a total tenure of roughly 42 years, averaging almost 3.0 years of service per executive, having 1.5 employees per reported executive. Analysis of Neurosense Therapeutics' management performance can provide insight into the firm performance.
Neurosense |
Neurosense Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (1.5079) % which means that it has lost $1.5079 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.9484) %, meaning that it created substantial loss on money invested by shareholders. Neurosense Therapeutics' management efficiency ratios could be used to measure how well Neurosense Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Neurosense Therapeutics' Return On Capital Employed is very stable compared to the past year. As of the 15th of December 2024, Return On Equity is likely to grow to 5.66, while Return On Tangible Assets are likely to drop (3.34). At this time, Neurosense Therapeutics' Total Assets are very stable compared to the past year. As of the 15th of December 2024, Net Tangible Assets is likely to grow to about 10.9 M, while Non Current Assets Total are likely to drop about 154 K.As of the 15th of December 2024, Common Stock Shares Outstanding is likely to grow to about 14.3 M, while Net Loss is likely to drop (3.8 M).
Neurosense Therapeutics Workforce Comparison
Neurosense Therapeutics is regarded fourth in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 175. Neurosense Therapeutics retains roughly 18.0 in number of employees claiming about 10% of equities under Health Care industry.
Neurosense Therapeutics Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Neurosense Therapeutics Price Series Summation is a cross summation of Neurosense Therapeutics price series and its benchmark/peer.
Neurosense Therapeutics Notable Stakeholders
A Neurosense Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Neurosense Therapeutics often face trade-offs trying to please all of them. Neurosense Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Neurosense Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Sharon Vered | Global CMC | Profile | |
| Diana Shtossel | Head Affairs | Profile | |
| Or Eisenberg | Chief Officer | Profile | |
| Nedira SalzmanFrenkel | Global Devel | Profile | |
| Yael Barak | Head Compliance | Profile | |
| Alon BenNoon | CEO CoFounder | Profile | |
| Hagit Binder | VP Operations | Profile | |
| Ferenc MD | Chief Officer | Profile | |
| Shiran Zimri | Head Program | Profile | |
| Keren Pushett | Head HR | Profile | |
| Eidan Loushi | CRA | Profile | |
| Niva RussekBlum | Global Generator | Profile |
About Neurosense Therapeutics Management Performance
The success or failure of an entity such as Neurosense Therapeutics often depends on how effective the management is. Neurosense Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Neurosense management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Neurosense management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (3.18) | (3.34) | |
| Return On Capital Employed | 42.58 | 44.70 | |
| Return On Assets | (3.18) | (3.34) | |
| Return On Equity | 5.39 | 5.66 |
Neurosense Therapeutics Workforce Analysis
Traditionally, organizations such as Neurosense Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Neurosense Therapeutics within its industry.Neurosense Therapeutics Manpower Efficiency
Return on Neurosense Therapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 626.7K | |
| Net Loss Per Executive | 940K |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurosense Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Neurosense Stock, please use our How to Invest in Neurosense Therapeutics guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurosense Therapeutics. If investors know Neurosense will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurosense Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.65) | Return On Assets (1.51) | Return On Equity (4.95) |
The market value of Neurosense Therapeutics is measured differently than its book value, which is the value of Neurosense that is recorded on the company's balance sheet. Investors also form their own opinion of Neurosense Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Neurosense Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurosense Therapeutics' market value can be influenced by many factors that don't directly affect Neurosense Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurosense Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurosense Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurosense Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.